| Name | Title | Contact Details |
|---|
ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies. In a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. We have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. We are also an 'end-to-end' Pharmacovigilance service provider and this includes Post Marketing Surveillance activities too.
Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.
SciMed Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Our proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Our initial focus is to advance RCT™ product candidates for the treatment cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. We are currently enrolling patients in a Phase 1/2 clinical trial of RTX-240; the trial has two Phase 1 arms enrolling adult patients with advanced solid tumors: an ongoing monotherapy dose escalation arm in adults with relapsed/refractory or locally advanced solid tumors and a combination therapy dose escalation arm with pembrolizumab in adults with relapsed/refractory or locally advanced solid tumors. In April 2022, the combination arm with pembrolizumab was expanded to focus on non-small cell lung cancer and renal cell carcinoma patients. We are also enrolling patients in a Phase 1/2 clinical trial of RTX-224 for the treatment of patients with certain advanced solid tumors, including non-small cell lung cancer, cutaneous melanoma, head and neck squamous cell carcinoma, urothelial (bladder) carcinoma and triple-negative breast cancer.
Mason District Hospital is a Havana, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.